Johnson & Johnson (NYSE:JNJ – Get Free Report)’s share price dropped 1.1% during mid-day trading on Monday following insider selling activity. The company traded as low as $282.33 and last traded at $282.6220. 7,837,458 shares were traded during trading, a decline of 1% from the average daily volume of 7,952,161 shares. The stock had previously closed at $285.75.
Specifically, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at $4,832,923.66. This trade represents a 43.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on JNJ shares. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Royal Bank Of Canada lowered their price target on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. Morgan Stanley lowered their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a report on Thursday, October 15th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. Finally, Erste Group Bank lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $275.92.
View Our Latest Stock Analysis on JNJ
More Johnson & Johnson News
Investors following JNJ have been watching these news items:
- Positive Sentiment: Blackstone Life Sciences will provide $750 million to fund OLN324’s Phase 3 trials, helping support development while sharing some of the program’s financial burden. Blackstone announces $750 million development funding agreement
- Positive Sentiment: J&J also presented new oncology and immunology pipeline data at the 2026 ASH meeting, including initial results for next-generation antibody therapies. The reports add to the company’s pipeline narrative, though they do not establish commercial success. J&J showcases new blood cancer data at ASH
- Neutral Sentiment: Ollin’s treatments remain investigational and require successful late-stage trials and regulatory approval. The deal could expand J&J’s eye-care portfolio, but returns depend on clinical and commercial execution.
Johnson & Johnson Trading Down 1.1%
The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average price is $266.97 and its 200-day moving average price is $249.85. The stock has a market capitalization of $680.36 billion, a P/E ratio of 42.82, a P/E/G ratio of 2.82 and a beta of 0.22.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in JNJ. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $28,000. Matrix Trust Co raised its stake in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Navigoe LLC lifted its position in Johnson & Johnson by 60.4% during the third quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after acquiring an additional 55 shares during the last quarter. Montgomery Financial Services LLC purchased a new stake in Johnson & Johnson during the second quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. purchased a new stake in Johnson & Johnson during the third quarter valued at approximately $52,000. 69.55% of the stock is owned by institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
